Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Relypsa: FDA Issuance of a CRL for ZS-9 is a Significant Positive (RLYP, Buy, $18.50)

Investment Thesis

The receipt of a CRL for ZS-9 delays its possible approval by perhaps one year or more which substantially…
Read more…